Activity of melflufen in RR MM patients with extramedullary disease in the phase 2 HORIZON study (OP-106): promising results in a high-risk population

Autores: Richardson, P. G. ; Mateos, M. V.; Rodríguez Otero, Paula; Norkin, M. ; Larocca, A.; Hassoun, H. ; Alegre, A.; Paner, A.; Leleu, X. ; Maisel, C. ; Mazumder, A. ; Harmenberg, J. ; Byrne, C. ; Zubair, H. ; Thuresson, S. ; Blade, J.